NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
Loading market information…
NASDAQ · PBM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Psyence Biomedical Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Psyence Biomedical Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$5.60+$0.09 (+1.63%)
GT Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.52% below the high.
$0.76-$0.15 (-16.31%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$3.75+$0.03 (+0.81%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.65-$0.01 (-1.07%)
Protagenic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.76% below the high.
